Study about impact of dilution of rocuronium bromide on onset time of neuromuscular blockade

Study about impact of dilution of rocuronium bromide on onset time of neuromuscular blockade - Study about impact of dilution of rocuronium bromide on onset time of neuromuscular blockade

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023404

Enrollment

106

Registered

2016-08-01

Start date

2016-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients undergoing general anesthesia

Interventions

Group 1 receive undiluted rocuronium 0.6 mg kg-1 over 5 seconds Group 2 receive diluted rosuronium 0.6 mg kg-1 in 20 ml 0.9% saline over 5 seconds

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with an ASA physical status 1 or 2, scheduled for elective surgery under general anesthesia using rocuronium and supraglottic device at the Ryukyu university hospital are recruited.

Exclusion criteria

Exclusion criteria: Patients with severe hepatic, renal, or cardiovascular disease, neuromuscular disease, a history of rocuronium allergy, body mass index >=25 kg/m2 were excluded.

Design outcomes

Primary

Measure	Time frame
Onset time of neuromuscular blockade	—

Secondary

Measure	Time frame
Duration 25% (time from the start of injection of NMBA until the T1 in the TOF or the single twitch has recovered to 25% of the final value), Duration TOF 0.9 (the time from start of injection of the NMBA until recovery of the TOF ratio to 0.9), rocuronium-induced withdrawal movement	—

Countries

Japan

Contacts

Public ContactMisuzu Hayashi

Ryukyu university hospital Department of anesthesiology

koba_shu1982@yahoo.co.jp098-895-1336

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026